HK Stock Market Move | SCIENTECH (02291) surged over 12% with the breakthrough in the global expansion of its self-developed MemoSorb process. It has recently completed its first planting in three countries including Italy.

SCIENTECH (02291) surged by more than 12%, as of the time of writing, it had increased by 12.21%, reaching 10.54 Hong Kong dollars, with a turnover of 1.58 billion Hong Kong dollars. On the news front, according to a message from SCIENTECHs official WeChat account, recently, SCIENTECH's independently developed MemoSorb biodegradable atrial septal defect (ASD) occluder and patent foramen ovale (PFO) occluder were successfully implanted for the first time in Italy at the Sant'Eugenio Hospital in Rome, marking a significant progress in SCIENTECH's globalization process, transitioning from "breakthroughs" to "deep development." At the same time, SCIENTECH's independently developed MemoSorb biodegradable atrial septal defect (ASD) occluder and patent foramen ovale (PFO) occluder, were successfully implanted in the first batch in Russia at the Bakulev National Medical Research Center for Cardiovascular Surgery in Moscow, marking the official entry of MemoSorb into the Russian clinical field, further advancing SCIENTECH's globalization process.